Skip to main content
Premium Trial:

Request an Annual Quote

Zisi Fotev, Noel Thomas Doheny, Peer Schatz, Thomas Tuschl, and John Rossi

Premium

Cenix BioScience has named Zisi Fotev as its new chief business officer.

Fotev joins Cenix from Atugen, where he served as vice president of business development. Prior to this, Cenix said, he served as head of licensing and strategic alliances at the pharmaceuticals division of Germany’s Merck.

Fotev holds a BS from the University of Western Australia and a PhD from the University of Tuebingen.


Qiagen said this week that it has appointed Noel Thomas Doheny as its vice president of solutions for molecular diagnostics. Doheny will be part of Qiagen’s new executive team and report directly to CEO Peer Schatz.

According to Qiagen, Doheny formerly served in key positions for ThermoBioStar, including president and director of strategic planning and business development.


In the latest issue of MIT’s Technology Review magazine, Rockefeller University researcher Thomas Tuschl was interviewed for an article highlighting RNA interference.

Also interviewed for the piece is John Rossi of the Beckman Research Institute of the City of Hope Cancer Center.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.